Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)-Reference-Cited by-同舟云学术

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

Published:2003-10 Issue:5 Volume:5 Page:659-667
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European Journal of Heart Failure

Author:

Cohn Jay N.¹,Pfeffer Marc A.²,Rouleau Jean³,Sharpe Norman⁴,Swedberg Karl⁵,Straub Matthias⁶,Wiltse Curtis⁷,Wright Theressa J.⁷,

Affiliation:

1. Cardiovascular Division, Mayo Mail Code 508; University of Minnesota Medical School; 420 Delaware Street SE Minneapolis MN 55455 USA

2. Brigham and Women's Hospital; Harvard Medical School; Boston MA USA

3. University of Toronto; Toronto Ont. Canada

4. University of Auckland; Auckland New Zealand

5. Sahlgrenska University Hospital; Göteborg Sweden

6. Solvay Pharmaceuticals B.V., Weesp; The Netherlands

7. Eli Lilly and Company; Indianapolis IN USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure;Cohn;N Engl J Med,1984

2. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II;Francis;Circulation,1993

3. Hormones regulatory cardiovascular function in patients with severe congestive heart failure and their relation to mortality;Swedberg;Circulation,1990

4. Adverse consequences of high sympathetic nervous activity in the failing human heart;Kaye;J Am Coll Cardiol,1995

5. Adrenergic effects on the biology of the adult mammalian cardiocyte;Mann;Circulation,1992

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal denervation benefits in chronic kidney disease: An updated review;Yemen Journal of Medicine;2024-09-15

2. Hypertension increases sympathetic neuron activity by enhancing intraganglionic cholinergic collateral connections;The Journal of Physiology;2024-06-21

3. Not first‐line antihypertensive agents, but still effective—The efficacy and safety of imidazoline receptor agonists: A network meta‐analysis;Pharmacology Research & Perspectives;2024-05-28

4. Eurasian Association of Cardiology (EAC)/ National Society of Heart Failure And Myocardial Disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2024);Eurasian heart journal;2024-05-27

5. Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement;Journal of Hypertension;2024-05-15